How I use hydroxyurea to treat young patients with sickle cell anemia
Top Cited Papers
Open Access
- 1 July 2010
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 115 (26) , 5300-5311
- https://doi.org/10.1182/blood-2009-04-146852
Abstract
Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and provides therapeutic benefit through multiple mechanisms of acKeywords
This publication has 108 references indexed in Scilit:
- Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseNew England Journal of Medicine, 2009
- Pharmacotherapy in sickle cell disease – state of the art and future prospectsBritish Journal of Haematology, 2009
- DNA polymorphisms at the BCL11A , HBS1L-MYB , and β- globin loci associate with fetal hemoglobin levels and pain crises in sickle cell diseaseProceedings of the National Academy of Sciences, 2008
- Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adultsProceedings of the National Academy of Sciences, 2007
- Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomyThe Journal of Pediatrics, 2004
- A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemiaThe Journal of Pediatrics, 2001
- Clinical and hematologic effects of hydroxyurea in children with sickle cell anemiaThe Journal of Pediatrics, 1996
- Stimulation of F-Cell Production in Patients with Sickle-Cell Anemia Treated with Cytarabine or HydroxyureaNew England Journal of Medicine, 1985
- Bone-Marrow Transplantation in a Patient with Sickle-Cell AnemiaNew England Journal of Medicine, 1984
- Effect of hydroxyurea on ribonucleotide reductaseBiochemical and Biophysical Research Communications, 1968